tradingkey.logo

Mesa Laboratories Inc

MLAB

69.170USD

+4.020+6.17%
Close 09/18, 16:00ETQuotes delayed by 15 min
380.54MMarket Cap
LossP/E TTM

Mesa Laboratories Inc

69.170

+4.020+6.17%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
69 / 207
Overall Ranking
181 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
88.500
Target Price
+35.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Its segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. It also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services quality control products. It has manufacturing operations in the United States and Europe.
Undervalued
The company’s latest PE is -556.92, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.60M shares, decreasing 8.81% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 388.10K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 1.06.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.12, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 59.54M, representing a year-over-year increase of 2.36%, while its net profit experienced a year-over-year increase of 39.96%.

Score

Industry at a Glance

Previous score
7.12
Change
0

Financials

6.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.88

Operational Efficiency

8.12

Growth Potential

6.55

Shareholder Returns

7.65

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -524.56, which is -99.58% below the recent high of -2.19 and 45.41% above the recent low of -286.37.

Score

Industry at a Glance

Previous score
1.20
Change
1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/207
No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Mesa Laboratories Inc is 88.50, with a high of 110.00 and a low of 67.00.

Score

Industry at a Glance

Previous score
7.33
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts
Buy
Current Rating
88.500
Target Price
+35.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Mesa Laboratories Inc
MLAB
3
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.63, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 72.62 and the support level at 58.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.63
Change
0.4

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
1.742
Neutral
RSI(14)
53.671
Neutral
STOCH(KDJ)(9,3,3)
75.311
Buy
ATR(14)
4.184
High Vlolatility
CCI(14)
137.322
Buy
Williams %R
12.673
Overbought
TRIX(12,20)
-0.403
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
65.446
Buy
MA10
63.994
Buy
MA20
65.754
Buy
MA50
69.712
Sell
MA100
88.334
Sell
MA200
109.412
Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 101.85%, representing a quarter-over-quarter decrease of 4.68%. The largest institutional shareholder is The Vanguard, holding a total of 388.10K shares, representing 7.05% of shares outstanding, with 0.42% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
739.18K
-1.89%
Conestoga Capital Advisors, LLC
571.36K
-0.29%
The Vanguard Group, Inc.
Star Investors
383.30K
+0.46%
Royce Investment Partners
Star Investors
271.12K
-5.60%
Ranger Investment Management, L.P.
230.99K
-1.10%
State Street Global Advisors (US)
219.54K
-2.38%
Geneva Capital Management LLC
189.31K
+0.16%
Atlanta Capital Management Company, L.L.C.
147.79K
-12.96%
Glenmede Investment Management LP
146.54K
-3.49%
Geode Capital Management, L.L.C.
137.52K
+10.50%
1
2

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.14, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.14
Change
0
Beta vs S&P 500 index
0.86
VaR
+4.41%
240-Day Maximum Drawdown
+62.88%
240-Day Volatility
+58.15%
Return
Best Daily Return
60 days
+9.50%
120 days
+11.10%
5 years
+15.27%
Worst Daily Return
60 days
-24.92%
120 days
-24.92%
5 years
-24.92%
Sharpe Ratio
60 days
-1.32
120 days
-1.35
5 years
-0.38
Risk Assessment
Maximum Drawdown
240 days
+62.88%
3 years
+71.81%
5 years
+82.72%
Return-to-Drawdown Ratio
240 days
-0.76
3 years
-0.21
5 years
-0.18
Skewness
240 days
-1.12
3 years
-0.41
5 years
-0.38
Volatility
Realised Volatility
240 days
+58.15%
5 years
+45.72%
Standardised True Range
240 days
+8.09%
5 years
+8.99%
Downside Risk-Adjusted Return
120 days
-164.75%
240 days
-164.75%
Maximum Daily Upside Volatility
60 days
+47.83%
Maximum Daily Downside Volatility
60 days
+61.39%
Liquidity
Average Turnover Rate
60 days
+2.98%
120 days
+1.92%
5 years
--
Turnover Deviation
20 days
+106.10%
60 days
+178.85%
120 days
+79.74%

Peer Comparison

Healthcare Equipment & Supplies
Mesa Laboratories Inc
Mesa Laboratories Inc
MLAB
6.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
8.20 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.19 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
8.09 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI